BioPharmSignal logoBioPharmSignal

Biotech News

Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness

Regeneron Pharmaceuticals (REGN)Regeneron PharmaceuticalsCompany update

Updated agreement expands 2020 procurement agreement with BARDA for Regeneron 's first-in-class antibody treatment for Orthoebolavirus zairense, adding value of approximately $270 million TARRYTOWN, N.Y., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.

Related news

REGNRegeneron Pharmaceuticals2026-11-02 21:05 EST

Regeneron Announces Investor Conference Presentations

REGNRegeneron Pharmaceuticals2026-10-06 11:00 EST

Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026

ENTAEnanta Pharmaceuticals2026-10-26 11:00 EST

Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)

JNJJohnson & Johnson2026-10-23 11:09 EST

European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) monotherapy for relapsed/refractory multiple myeloma, expanding treatment options from first relapse

IMVTImmunovant2026-10-21 11:00 EST

Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026

RVMDRevolution Medicines2026-10-20 12:00 EST

Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer

ENTAEnanta Pharmaceuticals2026-10-13 11:00 EST

Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026

RVMDRevolution Medicines2026-10-05 12:00 EST

Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer

BMYBMYBristol-Myers Squibb Company2026-11-06 21:00 EST

Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) for Camzyos (mavacamten) at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions

SNDXSyndax Pharmaceuticals2026-10-30 13:01 EST

Syndax’s Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases

View all latest news

Regeneron Pharmaceuticals

Integrated Biopharmaceutical Company Regeneron Pharmaceuticals discovers, develops, manufactures and commercializes medicines across ophthalmology, immunology, oncology, rare disease, cardiovascular medicine and other areas. Its internal technology platforms support a large clinical portfolio and multiple global collaborations. Retinal...

Recent company news

REGNRegeneron Pharmaceuticals2026-11-02 21:05 EST

Regeneron Announces Investor Conference Presentations

REGNRegeneron Pharmaceuticals2026-10-30 10:30 EST

Regeneron Reports Third Quarter 2026 Financial and Operating Results

REGNRegeneron Pharmaceuticals2026-10-26 11:00 EST

Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness

REGNRegeneron Pharmaceuticals2026-10-25 09:15 EST

Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)

REGNRegeneron Pharmaceuticals2026-10-16 11:00 EST

Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types

Stock data

Close
902.90 USD
Market cap
63.21B USD
Exchange
NASDAQ
Sector
Antibody Drugs, Biopharma
Location
United States